DOSSIER · 13F-HR · Q2 2026

Foresite Capital Management IV, LLC

$290M in tracked AUM across 6 positions as of Q2 2026.

FC
CIK 0001704132 · last filed Jun 30, 2026
Total AUM
$290M
as of Q2 2026
Holdings
6
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Foresite Capital Management IV, LLC (SEC 13F)
1. Portfolio Overview

Foresite Capital Management IV, LLC manages a highly concentrated, high-conviction portfolio totaling approximately $169.06 million as of September 30, 2025. The firm demonstrates a distinct lack of diversification, holding only 5 positions, which characterizes this as a high-risk, high-reward investment strategy typical of specialized healthcare or biotechnology-focused investment vehicle...

The portfolio experienced significant growth during the quarter, with the total value increasing by 36.6% (rising from $123.80M). This appreciation is likely driven by a combination of positive market performance in existing holdings and substantial capital inflows, evidenced by the aggressive purchasing activity in the top position. The management strategy favors focused exposure over broad risk mitigation, allocating the vast majority of capital to a select few opportunities.

2. Key Holdings

The portfolio is dominated by a single "bet" on Pharvaris N.V., which constitutes a massive 70.52% of the total portfolio value ($119.23M). This position was increased by 8.3% during the quarter, with an additional $41.60M deployed, bringing the total share count to 4.78M. This indicates an extremely high conviction in the company's prospects.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
N69605108
Pharvaris N.V.
$165M4.8M57.0%
02
CYTK
CYTOKINETICS INC
$61M715K21.0%
03
EIKN
Eikon Therapeutics, Inc.
$25M1.9M8.7%
04
RLAY
Relay Therapeutics, Inc.
$23M1.3M8.1%
05
XENE
Xenon Pharmaceuticals Inc.
$10M160K3.3%
06
CRNX
Crinetics Pharmaceuticals, Inc.
$6M150K1.9%

Filing history

2026Q2Jun 30
$290M 26.3%
6 positionsView →
2025Q4Dec 31
$230M 35.9%
7 positionsView →
2025Q3Sep 30
$169M 36.6%
5 positionsView →
2025Q2Jun 30
$124M 41.0%
6 positionsLocked
2025Q1Mar 31
$88M 19.3%
4 positionsLocked
2024Q4Dec 31
$109M 28.9%
4 positionsLocked
2024Q3Sep 30
$153M 2.8%
5 positionsLocked
2024Q2Jun 30
$149M 24.8%
4 positionsLocked
2024Q1Mar 31
$198M 0.0%
5 positionsLocked
2023Q4Dec 31
$198M 9.9%
5 positionsLocked
2023Q3Sep 30
$180M 11.5%
7 positionsLocked
2023Q2Jun 30
$203M 5.5%
7 positionsLocked
Showing 12 of 32